Eagle Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
J. Goldman & Co. LP, along with its affiliates, has reported a passive beneficial ownership of 5.1% in Eagle Pharmaceuticals, Inc. common stock.
OTC.Pink
Nantahala Capital Management, LLC and its managing members disclosed a significant beneficial ownership of 38.08% in Eagle Pharmaceuticals, Inc.
OTC.Pink
Nantahala Capital Partners Limited Partnership, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a passive beneficial ownership of 6.241% in Eagle Pharmaceuticals, Inc.
OTC.Pink
SCHEDULE 13G/A: Nantahala Capital Management Discloses Significant 38% Stake in Eagle Pharmaceuticals
Nantahala Capital Management, along with its principals Wilmot B. Harkey and Daniel Mack, has reported a substantial 38.078% beneficial ownership stake in Eagle Pharmaceuticals, Inc. as of February 16, 2025.
OTC.Pink
Union Square Park Partners, LP and affiliated entities have reported a beneficial ownership of 11.44% in Eagle Pharmaceuticals, Inc. common stock as of December 31, 2024.